121 related articles for article (PubMed ID: 17490733)
1. Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.
Albitar L; Carter MB; Davies S; Leslie KK
Gynecol Oncol; 2007 Jul; 106(1):94-104. PubMed ID: 17490733
[TBL] [Abstract][Full Text] [Related]
2. Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells.
Albitar L; Pickett G; Morgan M; Davies S; Leslie KK
Gynecol Oncol; 2007 Jul; 106(1):52-64. PubMed ID: 17490735
[TBL] [Abstract][Full Text] [Related]
3. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
4. CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
Maeda M; Murakami Y; Watari K; Kuwano M; Izumi H; Ono M
Lung Cancer; 2015 Mar; 87(3):265-71. PubMed ID: 25638724
[TBL] [Abstract][Full Text] [Related]
5. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.
Meng X; Laidler LL; Kosmacek EA; Yang S; Xiong Z; Zhu D; Wang X; Dai D; Zhang Y; Wang X; Brachova P; Albitar L; Liu D; Ianzini F; Mackey MA; Leslie KK
Gynecol Oncol; 2013 Mar; 128(3):461-9. PubMed ID: 23146687
[TBL] [Abstract][Full Text] [Related]
6. [Effect of signal transduction inhibitors on human endometrial carcinoma cells with differential PTEN gene expression].
Xiao L; Yang YB; Shen HM; Xu CF; Wang XY; Li XM
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):681-5. PubMed ID: 20079181
[TBL] [Abstract][Full Text] [Related]
7. Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.
Albitar L; Laidler LL; Abdallah R; Leslie KK
Mol Cancer Ther; 2005 Dec; 4(12):1891-9. PubMed ID: 16373704
[TBL] [Abstract][Full Text] [Related]
8. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Kokubo Y; Gemma A; Noro R; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Shibuya M; Kudoh S
Br J Cancer; 2005 May; 92(9):1711-9. PubMed ID: 15870831
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
11. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
12. An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells.
Chang GC; Yu CT; Tsai CH; Tsai JR; Chen JC; Wu CC; Wu WJ; Hsu SL
Eur J Pharmacol; 2008 Dec; 600(1-3):37-44. PubMed ID: 18973751
[TBL] [Abstract][Full Text] [Related]
13. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
Rho JK; Choi YJ; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
Cancer Res; 2007 Feb; 67(3):1163-9. PubMed ID: 17283151
[TBL] [Abstract][Full Text] [Related]
14. PTEN augments doxorubicin-induced apoptosis in PTEN-null Ishikawa cells.
Wan X; Li J; Xie X; Lu W
Int J Gynecol Cancer; 2007; 17(4):808-12. PubMed ID: 17359293
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
Janmaat ML; Rodriguez JA; Gallegos-Ruiz M; Kruyt FA; Giaccone G
Int J Cancer; 2006 Jan; 118(1):209-14. PubMed ID: 16003751
[TBL] [Abstract][Full Text] [Related]
16. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
Zhou M; Gu L; Findley HW; Jiang R; Woods WG
Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
[TBL] [Abstract][Full Text] [Related]
17. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
18. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
20. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
